BOLD
Boundless Bio, Inc.
2.60$
+1.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
Boundless Bio, Inc. (BOLD) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -21 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -10 | -13 | -23 | -16 | -23 | -23 | -25 | -23 | -32 | -28 | -42 | -41 | -36 | -11 | -10 | -12 | -11 | -12 | -12 | -16 | -16 | -13 | -16 | -15 | -12 | -10 | -10 | -15 | -21 | -56 | |
| 0.6 | 0.8 | 0.8 | 0.8 | 1.0 | 1.2 | 1.3 | 1.5 | 1.2 | 3.5 | 2.3 | 2.7 | 5.6 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 1.3 | 2.2 | |
| 0.6 | 0.7 | 1.1 | 1.5 | 1.5 | 2.8 | 3.4 | 4.1 | 4.6 | 4.4 | 5.5 | 6.1 | 5.7 | 0.6 | 0.6 | 0.6 | 0.9 | 0.9 | 0.9 | 1.3 | 2.1 | 2.0 | 2.0 | 1.8 | 1.7 | 1.3 | 1.3 | 1.4 | 4.6 | 8.6 | |
| 58 | -19 | -19 | 57 | 13 | -28 | 194 | -11 | -37 | 130 | -49 | 18 | -37 | 0.7 | 0.3 | -1.7 | 0.5 | 0.5 | -0.2 | -1.6 | -0.6 | 1.6 | -1.1 | -0.9 | 1.7 | 1.8 | 0.8 | -3.6 | -9.5 | -10 | |
| 5.5 | 2.3 | 0.8 | 1.5 | 2.8 | 2.5 | 0.9 | 4.4 | 2.7 | 3.5 | 1.3 | 4.4 | 4.4 | 0.1 | 0.0 | 0.1 | 0.1 | 0.2 | 0.3 | 0.1 | 1.5 | 0.5 | 0.5 | 0.1 | 0.0 | 0.0 | 0.4 | 0.0 | 0.0 | 0.5 | |
| 9.4 | -38 | 4.8 | -29 | -15 | 5.4 | -1.4 | -8.8 | -80 | -95 | 28 | -41 | -12 | 8.5 | 8.4 | 22 | -69 | -7.7 | 16 | 18 | -68 | 22 | 1.8 | 3.1 | 11 | 10 | 13 | 15 | 23 | 61 | |
| -75 | 51 | -19 | -36 | 1.0 | 15 | -231 | 16 | 110 | -40 | -133 | 34 | 35 | – | – | – | – | – | – | – | – | – | – | – | 0.1 | – | 0.0 | – | 0.0 | – | |
| 75 | 0.0 | 0.1 | 81 | 37 | 2.9 | 218 | 16 | 1.3 | 164 | 3.0 | 48 | 12 | 0.0 | 0.0 | 0.0 | 100 | -0.4 | -1.4 | -0.9 | 91 | 0.0 | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 | – | 0.1 | – | |
| 75 | -51 | -18 | 36 | -1.0 | -15 | 192 | -16 | -110 | 40 | -11 | -34 | -35 | -2.2 | -1.8 | -11 | 20 | -20 | 2.7 | 1.4 | 6.2 | 8.9 | -14 | -11 | -0.4 | 0.3 | 2.9 | -0.4 | 2.7 | 5.5 | |
| -16 | -15 | -23 | -18 | -26 | -25 | -26 | -28 | -34 | -32 | -44 | -45 | -40 | -11 | -10 | -12 | -11 | -12 | -12 | -16 | -18 | -14 | -16 | -15 | -12 | -10 | -11 | -15 | -21 | -57 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.